ECONOMIC EVALUATION OF NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED MELANOMA IN CANADA

被引：0
|
作者：
Quon, P. [1 ]
Xiao, Y. [2 ]
Sorensen, S. [1 ]
Schultz, M. [3 ]
Monfared, Tahami A. A. [3 ]
机构：
[1] Evidera, Bethesda, MD USA
[2] Evidera Inc, London, England
[3] Bristol Myers Squibb, Montreal, PQ, Canada
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.248
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN165
引用
收藏
页码：A441 / A442
页数：2
相关论文
共 50 条
  • [1] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
    Peter L. Quon
    Ying Xiao
    Sonja Sorensen
    Amir Abbas Tahami Monfared
    PharmacoEconomics - Open, 2019, 3 : 321 - 331
  • [2] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
    Quon, Peter L.
    Xiao, Ying
    Sorensen, Sonja
    Monfared, Amir Abbas Tahami
    PHARMACOECONOMICS-OPEN, 2019, 3 (03) : 321 - 331
  • [3] Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan
    Paly, Victoria Federico
    Hikichi, Yusuke
    Baker, Timothy
    Itakura, Eijun
    Chandran, Nisha
    Harrison, James
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1542 - 1552
  • [4] Survival of responders to nivolumab (NIVO) plus ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1
    Brahmer, J. R.
    Ciuleanu, T-E.
    Schenker, M.
    Audigier-Valette, C.
    Zurawski, B.
    Linardou, H.
    Kim, S-W.
    Otterson, G. A.
    Salman, P.
    De La Mora Jimenez, E.
    Lesniewski-Kmak, K.
    Ahmed, S.
    Albert, I.
    Barlesi, F.
    Feeney, K.
    Frickhofen, N.
    Li, A.
    Sun, P.
    Hellmann, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1444 - S1445
  • [5] Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO plus RELA) versus NIVO plus ipilimumab (NIVO plus IPI) in advanced melanoma: An updated indirect treatment comparison (ITC)
    Schadendorf, Dirk
    Tawbi, Hussein A.
    Lipson, Evan J.
    Hodi, F. Stephen
    Ascierto, Paolo Antonio
    Larkin, James
    Lao, Christopher D.
    Grob, Jean-Jacques
    Ejzykowicz, Flavia
    Palaia, Jennell
    Horton, Viviana Garcia
    Zhou, Zheng-Yi
    Christensen, Dana
    Rosenblatt, Lisa
    McDonald, Laura
    Ratto, Barbara
    Salvatore, Anthony
    Patel, Divya
    Sakkal, Leon A.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] SAFETY PROFILE OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) COMBINATION THERAPY IN PATIENTS WITH ADVANCED MELANOMA (MEL)
    Sznol, Mario
    Ferrucci, Pier
    Hogg, David
    Atkins, Michael
    Wolter, Pascal
    Guidoboni, Massimo
    Lebbe, Celeste
    Kirkwood, John
    Schachter, Jacob
    Daniels, Gregory
    Hassel, Jessica
    Cebon, Jonathan
    Gerritsen, Winald
    Atkinson, Victoria
    Thomas, Luc
    Mccaffrey, John
    Power, Derek
    Jiang, Joel
    Hodi, Stephen
    Wolchok, Jedd
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 118 - 118
  • [7] Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)
    Sznol, M.
    Ferrucci, P. F.
    Hogg, D.
    Atkins, M.
    Wolter, P.
    Guidoboni, M.
    Lebbe, C.
    Kirkwood, J.
    Schachter, J.
    Daniels, G.
    Hassel, J.
    Cebon, J.
    Gerritsen, W.
    Atkinson, V.
    Thomas, L.
    McCaffrey, J.
    Power, D.
    Jiang, J.
    Hodi, F. S.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Characterisation of Complete Responses (CRS) in Patients With Advanced Melanoma (MEL) who Received the Combination of Nivolumab (NIVO) and Ipilimumab (IPI), NIVO, or IPI Alone
    Robert, Caroline
    Larkin, James
    Ascierto, Paolo A.
    Long, Georgina V.
    Hassel, Jessica C.
    Schadendorf, Dirk
    Hodi, F. Stephen
    Lebbe, Celeste
    Grob, Jean-Jacques
    Grossmann, Kenneth
    Wagstaff, John
    Chesney, Jason
    Hogg, David
    Bechter, Oliver
    Marquez-Rodas, Ivan
    Pavlick, Anna C.
    DanaWalker
    Bhore, Rafia
    Postow, Michael A.
    Wolchok, Jedd D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 136 - 137
  • [9] Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone
    Robert, C.
    Larkin, J.
    Ascierto, P. A.
    Long, G. V.
    Hassel, J. C.
    Schadendorf, D.
    Hodi, F. S.
    Lebbe, C.
    Grob, J-J.
    Grossmann, K.
    Wagstaff, J.
    Chesney, J.
    Hogg, D.
    Bechter, O.
    Marquez-Rodas, I.
    Pavlick, A. C.
    Walker, D.
    Bhore, R.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Assessment of real-world effectiveness of first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) or NIVO monotherapy for advanced melanoma: A retrospective cohort study
    Freeman, M.
    Gupte-Singh, K.
    You, M.
    Le, T. K.
    Ritchings, C.
    Rao, S.
    Jang, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 457 - 457
12345